Understanding the Biological Barriers in Nanomedicine

Cellular Barriers

After crossing the physiological barriers, nanoparticles experience cell barriers that impact the particles’ uptake, transport, and internalization.

Cellular Uptake

The particles are internalized within the cells through endocytosis, phagocytosis, and pinocytosis; these are the processes of the cell. The following are some of the parameters that affect uptake by the cells and include the size and geometry of the nanoparticles, charge, and functionalization of the nanoparticles.

For example, the large size of nanoparticles can affect uptake by indicating that small particles are more readily taken up than large ones. Even though passive targeting with surface modification using antibodies or peptides can up-regulate the endocytosis and cellular uptake of nanoparticles.

Intracellular Trafficking

Once internalized, the nanoparticles have to move within cells to their target sites, the cytoplasm or nucleus. Endosomal and lysosomal targeting is another process that seems to take place within the scaffolds of cellular powerhouses; nanoparticles can be degraded here. Measures for targeted delivery of the therapeutic molecules to the targeted endosomal compartments for evading entrapment are in development, for instance, pH-sensitive or enzyme-sensitive nanoparticles.

Molecular Barriers

At the molecular level, nanoparticles’ problems involve stability and/or controlled release of the drug and interaction with biological molecules.

Stability and Release

Nanoparticles should be able to protect and stabilize the drugs, genes, or other therapeutic molecules after their administration in the body and only release them at the particular site desired. Therapeutic agents become less effective and may turn toxic if suddenly released or degraded early from the body. They are used for shielding the therapeutic agents and releasing them in a controlled manner in response to stimuli like changes in pH or temperature.

Protein Binding

Nanoparticles tend to interact with different proteins in the biological environment, which will influence the stability, distribution, and internalization of the nanoparticles. Thus, general knowledge and ways to influence protein manners of interacting with nanoparticles are critical to defining optimal conditions for the nanoparticles’ work. Another typical method applied to decrease the extent of protein adsorption depends on the modification of the nanoparticles; they are coated with polyethylene glycol (PEG), also called PEGylation.

Innovative Strategies to Overcome Biological Barriers

The biological barriers of the enteral route continue to present researchers with new problems in nanomedicine, and there are new approaches to solving these problems. Some of these strategies are surface modification, biomimicry, and the use of multifunctional nanoparticles.

Surface Modification: Targeting ligands could be used to coat the surface of nanoparticles; it could be an antibody, peptide, or small molecule that increases the nanoparticles affinity for their target cell or tissue. An example is that nanoparticles that are coated with transferrin can selectively deliver drugs to cancer cells because those cells over-express transferrin receptors.

Biomimicry: Biomimetism is the process of engineering new nanoparticles to imitate viruses or cells to increase their performance in biological environments. For example, virus-like nanoparticles can easily penetrate the cell through mimicry of viral mechanisms. Likewise, any nanoparticles that are surrounded by a cell membrane from red blood cells or platelets are hiding from the immune system, with extended circulation time.

Multifunctional Nanoparticles: Dual-purpose nanoparticles are those that should be expected to perform more than one task at a given instance or at a different time, and these include targeting, imaging, and therapy. Such types of nanoparticles can be prepared in such a manner that they will disintegrate the therapeutic agents or drugs if they encounter some stimuli in the biological system, and at the same time, it is possible to monitor the treatment outcome. 

For instance, magnetic nanoparticles can be guided to the area of interest using an external magnetic field, while on the other hand, gold nanoparticles can be used for imaging in addition to the destruction of body tissues using photothermal therapy.

Applications of Case Studies and Clinical Trials

It presents some case studies and clinical applications of advanced achievements in the field and the corresponding problems of eliminating biological barriers in nanomedicine.

CRLX101 Nanoparticles: CRLX101 is a nanoparticle-drug conjugate that incorporates camptothecin, an effective anticancer agent, into the affected site. The formulation of camptothecin on a nanoparticle basis improves its stability and solubility, thus expanding its circulation time and enhancing its localization in tumor areas. From the above descriptions of the mechanism of action, efficacy, and safety, it can be deduced that CRLX101 holds great potential in the treatment of cancer since it has hailed the cancer research community through the following:

Dual HER2 Targeting Nanoparticles: New nanoparticles intended to selectively bind with HER2 receptors on cancer cells have been created to increase targeted cancer treatment. These nanoparticles are conjugated first with trastuzumab, which is an antibody against HER2, and second with liposome-encapsulated doxorubicin. The strategy of dual targeting is specific to deliver the drug at the site of the disease and, therefore, avoid side effects.

Protein Corona Fingerprints: Data on protein corona, the layer of proteins that form on nanoparticles as soon as they enter the bloodstream, will assist in the design of a better nanoparticle. In the works that were published by other authors, it was demonstrated that the protein corona influences the recognition of a nanoparticle by the immune system and determines its biodistribution and cellular accumulation.

Future Perspectives: Nanomedicine is a progressing field of study, and the study of biological barriers and enhancing the applications of nanoparticles for treatment is an area of research that is still being researched today. The constant innovation process in materials science and biotechnology, along with nanotechnology, is forcing the creation of the next generation of nanoparticles with better target specificity, stability, and therapeutic efficiency. This study implies that multisectoral approaches involving both research and practice and cooperation between health professionals and policymakers are needed to solve these issues and enhance the implementation of nanomedicine research findings into practice.

Conclusion

Appreciating and eliminating biological challenges to nanomedicine are significant prerequisites for exploiting the nanoparticle delivery system for the optimum antitumor effect. Therefore, by overcoming the aforementioned physiological, cellular, and molecular challenges, scientists can envision and create novel nanoparticles for better understanding and overcoming the biological barriers, effectively delivering the intended therapeutic agents to the target location and paving the way to the intended clinical benefits. The positive development of nanomedicine also proclaims hope for evolving disease treatment regimes and enhancing patients’ experiences.

References

1. Xu X, Wu J, Liu Y, Yu M, Zhao L, Zhu X, Bhasin S, Li Q, Ha E, Shi J, Farokhzad OC. Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy. Angew Chem Int Ed Engl. 2016 Jun 13;55(25):7091-7094. doi: 10.1002/anie.201601273. Epub 2016 May 3. PMID: 27140428; PMCID: PMC4972612.
2. Czapar, A.E., Zheng, Y.R., Riddell, I.A., Shukla, S., Awuah, S.G., Lippard, S.J. and Steinmetz, N.F., 2016. Tobacco mosaic virus delivery of phenanthriplatin for cancer therapy. ACS nano, 10(4), pp.4119-4126.
3. Li, H.J., Du, J.Z., Du, X.J., Xu, C.F., Sun, C.Y., Wang, H.X., Cao, Z.T., Yang, X.Z., Zhu, Y.H., Nie, S. and Wang, J., 2016. Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proceedings of the National Academy of Sciences, 113(15), pp.4164-4169.
4. Clark, A.J., Wiley, D.T., Zuckerman, J.E., Webster, P., Chao, J., Lin, J., Yen, Y. and Davis, M.E., 2016. CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing. Proceedings of the National Academy of Sciences, 113(14), pp.3850-3854.
5. Espelin, C.W., Leonard, S.C., Geretti, E., Wickham, T.J. and Hendriks, B.S., 2016. Dual HER2 targeting with trastuzumab and liposomal-encapsulated doxorubicin (MM-302) demonstrates synergistic antitumor activity in breast and gastric cancer. Cancer research, 76(6), pp.1517-1527.
6. Bigdeli A, Palchetti S, Pozzi D, Hormozi-Nezhad MR, Baldelli Bombelli F, Caracciolo G, Mahmoudi M. Exploring Cellular Interactions of Liposomes Using Protein Corona Fingerprints and Physicochemical Properties. ACS Nano. 2016 Mar 22;10(3):3723-37. doi: 10.1021/acsnano.6b00261. Epub 2016 Feb 23. PMID: 26882007.
7. Ashton S, Song YH, Nolan J, Cadogan E, Murray J, Odedra R, Foster J, Hall PA, Low S, Taylor P, Ellston R, Polanska UM, Wilson J, Howes C, Smith A, Goodwin RJ, Swales JG, Strittmatter N, Takáts Z, Nilsson A, Andren P, Trueman D, Walker M, Reimer CL, Troiano G, Parsons D, De Witt D, Ashford M, Hrkach J, Zale S, Jewsbury PJ, Barry ST. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci Transl Med. 2016 Feb 10;8(325):325ra17. doi: 10.1126/scitranslmed.aad2355. PMID: 26865565.